Inflammation-Modulating Effect of Butyrate in the Prevention of Colon Cancer by Dietary Fiber


      The intestinal microbiota plays key roles in human health, and adverse dysbiosis shifts of the microbiota have been associated with chronic diseases, including large bowel cancer. High-fiber diets may reduce the risk for large bowel cancer in association with gut microbiota modulation and butyrate production. Butyrate can inhibit histone deacetylases and associated signaling pathways in cultured cancer cells, promoting cancer cell apoptosis. However, butyrate has prevented colon cancer through the regulation of immune homeostasis rather than histone deacetylases inhibition. It could be important to further examine the pathways of how butyrate encourages immune system changes. We posited that butyrate-activated T-regulatory cells block proinflammatory T cells and thus reduce proinflammatory cytokine production; these cytokines increase cell proliferation and cell survival, the 2 most important cancer cell characteristics. Butyrate can exert anticancer effects through inhibition of multiple signaling pathways. It is possible that a low concentration of butyrate could modulate the immune system before other pathways to exert an anticancer effect. Increasing the concentration of butyrate in the intestines may produce a synergistic inhibitory signaling pathway response and an anti-inflammatory effect.


      To read this article in full you will need to make a payment


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sender R.
        • Fuchs S.
        • Milo R.
        Revised estimates for the number of human and bacteria cells in the body.
        PLoS Biol. 2016; 14: e1002533
        • Park S.Y.
        • Wilkens L.R.
        • Kolonel L.N.
        • Henderson B.E.
        • Le Marchand L.
        Inverse associations of dietary fiber and menopausal hormone therapy with colorectal cancer risk in the Multiethnic Cohort Study.
        Int J Cancer. 2016; 139: 1241-1250
        • Hamer H.M.
        • Jonkers D.
        • Venema K.
        • Vanhoutvin S.
        • Troost F.J.
        • Brummer R.J.
        Review article: the role of butyrate on colonic function.
        Aliment Pharmacol Ther. 2008; 27: 104-119
        • Gantois I.
        • Ducatelle R.
        • Pasmans F.
        • et al.
        Butyrate specifically down-regulates salmonella pathogenicity island 1 gene expression.
        Appl Environ Microbiol. 2006; 72: 946-949
        • O’Keefe S.J.
        Diet, microorganisms and their metabolites, and colon cancer.
        Nat Rev Gastroenterol Hepatol. 2016; 13: 691-706
        • Shaw E.
        • Warkentin M.T.
        • McGregor S.E.
        • Town S.
        • Hilsden R.J.
        • Brenner D.R.
        Intake of dietary fibre and lifetime non-steroidal anti-inflammatory drug (NSAID) use and the incidence of colorectal polyps in a population screened for colorectal cancer.
        J Epidemiol Community Health. 2017; 71: 961-969
        • Kopp T.I.
        • Vogel U.
        • Tjonneland A.
        • Andersen V.
        Meat and fiber intake and interaction with pattern recognition receptors (TLR1, TLR2, TLR4, and TLR10) in relation to colorectal cancer in a Danish prospective, case–cohort study.
        Am J Clin Nutr. 2018; 107: 465-479
        • Zhang M.
        • Zhou Q.
        • Dorfman R.G.
        • et al.
        Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats.
        BMC Gastroenterol. 2016; 16: 84
        • Zeng H.
        • Taussig D.P.
        • Cheng W.H.
        • Johnson L.K.
        • Hakkak R.
        Butyrate inhibits cancerous HCT116 colon cell proliferation but to a lesser extent in noncancerous NCM460 colon cells.
        Nutrients. 2017; 9: 25
        • Bishehsari F.
        • Engen P.A.
        • Preite N.Z.
        • et al.
        Dietary fiber treatment corrects the composition of gut microbiota, promotes SCFA production, and suppresses colon carcinogenesis.
        Genes. 2018; 9
        • Greten F.R.
        • Eckmann L.
        • Greten T.F.
        • et al.
        IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
        Cell. 2004; 118: 285-296
        • Park E.J.
        • Lee J.H.
        • Yu G.Y.
        • et al.
        Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.
        Cell. 2010; 140: 197-208
        • Potten C.S.
        • Kellett M.
        • Roberts S.A.
        • Rew D.A.
        • Wilson G.D.
        Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine.
        Gut. 1992; 33: 71-78
        • Zhao R.
        • Michor F.
        Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution.
        PLoS Comput Biol. 2013; 9: e1003082
        • Johnson D.E.
        • O’Keefe R.A.
        • Grandis J.R.
        Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
        Nat Rev Clin Oncol. 2018; 15: 234-248
        • Ibrahim S.
        • Girault A.
        • Ohresser M.
        • et al.
        Monoclonal antibodies targeting the IL-17/IL-17RA axis: an opportunity to improve the efficiency of anti-VEGF therapy in fighting metastatic colorectal cancer?.
        Clin Colorectal Cancer. 2018; 17: e109-e113
        • Lee H.H.
        • Yang S.S.
        • Vo M.T.
        • et al.
        Tristetraprolin down-regulates IL-23 expression in colon cancer cells.
        Molecules Cells. 2013; 36: 571-576
        • Pikarsky E.
        • Porat R.M.
        • Stein I.
        • et al.
        NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
        Nature. 2004; 431: 461-466
        • Font-Burgada J.
        • Sun B.
        • Karin M.
        Obesity and cancer: the oil that feeds the flame.
        Cell Metab. 2016; 23: 48-62
        • Kitamura H.
        • Ohno Y.
        • Toyoshima Y.
        • et al.
        Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
        Cancer Sci. 2017; 108: 1947-1952
        • Maeda S.
        • Omata M.
        Inflammation and cancer: role of nuclear factor–kappaB activation.
        Cancer Sci. 2008; 99: 836-842
        • Yen D.
        • Cheung J.
        • Scheerens H.
        • et al.
        IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
        J Clin Invest. 2006; 116: 1310-1316
        • Punkenburg E.
        • Vogler T.
        • Buttner M.
        • et al.
        Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer.
        Gut. 2016; 65: 1139-1150
        • Singh N.
        • Gurav A.
        • Sivaprakasam S.
        • et al.
        Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis.
        Immunity. 2014; 40: 128-139
        • Chaudhry A.
        • Rudra D.
        • Treuting P.
        • et al.
        CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner.
        Science. 2009; 326: 986-991